Camrelizumab in Combination With Apatinib Plus NK Cell in Patients With Advanced Hepatocellular Carcinoma (CAN): A First-line, Phase-II, Single-arm Trial
Latest Information Update: 04 Jan 2024
At a glance
- Drugs Camrelizumab (Primary) ; Natural killer cell therapy (Primary) ; Rivoceranib (Primary)
- Indications Liver cancer
- Focus Therapeutic Use
Most Recent Events
- 03 Jan 2022 New trial record